aTyr Pharma is a biotherapeutics company engaged in the discovery and development of medicines based on biological pathways. Co.'s primary therapeutic candidate efzofitimod, which is a fusion protein comprised of the immunomodulatory domain of histidyl-tRNA synthetase fused to the fragment crystallizable region of a human antibody. In parallel with Co.'s clinical development of efzofitimod, Co. has been improving its discovery pipeline of NRP2 antibodies and tRNA synthetases. Co.'s investigational new drug candidate ATYR2810, which is a humanized monoclonal antibody that blocks the interaction between NRP2 and one of its primary ligands, vascular endothelial growth factor. We show 37 historical shares outstanding datapoints in our LIFE shares outstanding history coverage, used to compute LIFE market cap on those dates.
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing LIFE market cap history over the course of time is important for investors
interested in comparing LIFE's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of LIFE versus a peer is one thing; comparing
LIFE market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like LIFE can fluctuate over the course of history.
With this page we aim to empower investors researching LIFE by allowing them to research the LIFE market cap history. |
Free LIFE Email Alerts:
Video: The Importance of Market Cap
